We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
HLUN-A.CO

Price
23.40
Stock movement down
-1.50 (-6.02%)
Company name
H Lundbeck A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
4.65B
Ent value
12.01B
Price/Sales
0.22
Price/Book
0.20
Div yield
-
Div growth
-
Growth years
-
FCF payout
14.06%
Trailing P/E
1.73
Forward P/E
-
PEG
-
EPS growth
-34.84%
1 year return
-18.75%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-04-10

DIVIDENDS

HLUN-A.CO does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E1.73
Price to OCF0.86
Price to FCF0.94
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales0.22
Price to Book0.20
EV to Sales0.56

FINANCIALS

Per share

Per share data
Current share count198.68M
EPS (TTM)2.70
FCF per share (TTM)4.96

Income statement

Income statement data
Revenue (TTM)21.47B
Gross profit (TTM)17.01B
Operating income (TTM)3.35B
Net income (TTM)2.69B
EPS (TTM)2.70
EPS (1y forward)-

Margins

Margins data
Gross margin (TTM)79.22%
Operating margin (TTM)15.61%
Profit margin (TTM)12.52%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash8.32B
Net receivables0.00
Total current assets17.00B
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets39.52B
Accounts payable4.26B
Short/Current long term debt4.19B
Total current liabilities7.78B
Total liabilities15.68B
Shareholder's equity23.84B
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)5.42B
Capital expenditures (TTM)485.00M
Free cash flow (TTM)4.94B
Dividends paid (TTM)694.00M

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity11.27%
Return on Assets6.80%
Return on Invested Capital11.24%
Cash Return on Invested Capital20.64%

STOCK INFORMATION

Stock chart

Stock price data
Open24.45
Daily high24.45
Daily low23.40
Daily Volume146K
All-time high41.55
1y analyst estimate-
Beta0.18
EPS (TTM)2.70
Dividend per share-
Ex-div date27 Mar 2025
Next earnings date14 May 2025

Downside potential

Downside potential data
HLUN-A.COS&P500
Current price drop from All-time high-43.68%-10.49%
Highest price drop-43.68%-56.47%
Date of highest drop9 Apr 20259 Mar 2009
Avg drop from high-18.99%-11.07%
Avg time to new high72 days12 days
Max time to new high313 days1805 days
COMPANY DETAILS
HLUN-A.CO (H Lundbeck A/S) company logo
Marketcap
4.65B
Marketcap category
Mid-cap
Description
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
Employees
5800
Website
https://www.lundbeck.com
Investor relations
-
SEC filings
HLUN-A.CO SEC filings
CEO
Country
Denmark
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in a...
March 13, 2025
Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal
Danish pharmaceutical company Lundbeck will buy Longboard Pharmaceuticals (LBPH) in a deal valued at $2.6 billion, with the former hoping to build off of its pipeline of epilepsy drug treatment. Marke...
October 14, 2024
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved